Other Clinical Trial - Lipid Biomarkers for Diabetic Heart Disease

Status Completed

Clinical Trial Summary

This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.

Clinical Trial Description

Screening procedures include 12-hour fasting blood draw, urine pregnancy testing for females, completion of medical history questionnaire, and stress echocardiography to rule out coronary artery disease or cardiomyopathy.

Subjects who meet screening criteria will return for visit 2, which consists of a urine collection, 12-hour fasting blood draw, dual-energy X-ray absorptiometry (DXA) for body composition, magnetic resonance spectroscopy analysis of the liver, and resting echocardiogram for analysis of heart structure and function. Subjects will then be randomized to treatment with fenofibrate (160 mg/d) or an identical-appearing placebo for 12 weeks. They will be asked to continue their usual medications, diet and physical activity. Subjects will receive a pedometer to wear daily to track their physical activity. Subjects will meet with dietitians from the Lifestyle Intervention Core to complete a 24-hour dietary recall. They will be instructed to record their daily blood glucose concentrations, distance walked and any side effects, illnesses or stresses in a study-supplied log. Subjects will be instructed to either email or fax the log to the study coordinator each week (or discuss by phone).

Subjects will return 6 weeks after starting intervention for visit 3 to ensure their medical safety. Procedures at this visit include an interim medical history, urine pregnancy test for females, blood draw to rule out untoward effects of the study drug on liver or kidney function, pill count to assess compliance, review of logs of blood glucose, distance walked, and side effects, illnesses or stresses, and meeting with a dietitian for a 24-hour dietary recall.

Subjects will continue to take their study medication/placebo and keep logs of blood glucose levels, distance walked, and side effects, illnesses and stresses for another 6 weeks. They will return for visit 4 after 12 total weeks of intervention. Visit 4 involves a urine collection, 12-hour fasting blood draw, review of subject logs, pill count, and 24-hour dietary recall. In addition, magnetic resonance spectroscopy analysis of the liver and resting echocardiogram analysis of the heart will be performed to determine if there have been any changes in liver fat or heart function during the 12-week intervention. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01752842
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Completed
Phase	N/A
Start date	March 2013
Completion date	February 23, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03022721` - Heidelberg Study on Diabetes and Complications	N/A
Withdrawn	`NCT02580266` - Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes
Completed	`NCT02423434` - Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
Completed	`NCT03426566` - Abnormal Plantar Pressure in Patients With Diabetes
Completed	`NCT01695278` - A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community	Phase 3
Completed	`NCT02588898` - B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes
Completed	`NCT00815178` - Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness	N/A
Not yet recruiting	`NCT04537676` - Patient Empowerment Study
Terminated	`NCT02915263` - The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes	Phase 2
Completed	`NCT01929018` - Collaborative-care Rehabilitation After Dysvascular Amputation	N/A
Completed	`NCT03877523` - Cocarnit Effects on Macrophages Polarization	N/A
Completed	`NCT02928939` - Therapeutic Conflicts and Multimorbidity
Completed	`NCT02947828` - Polyneuropathy in Diabetes Mellitus Type 2
Recruiting	`NCT02275091` - Children With Diabetes at Risk for Heart Disease.
Terminated	`NCT00529204` - Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease	Phase 2
Not yet recruiting	`NCT05074849` - Benefits of Insoles With Real-Time Alert and Foot Self-Care Education	N/A
Completed	`NCT04963998` - Safety and Efficacy Study of MedCu Wound Dressings	N/A
Recruiting	`NCT06321029` - Electronic Diabetes Tune-Up Group (eDTU) for African Americans	N/A
Active, not recruiting	`NCT03620773` - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes	Phase 1/Phase 2
Completed	`NCT05231642` - Individualised Postprandial Glucose Responses in Type 1 Diabetes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.